{"disease":{"id":"progression","name":"progression"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"atorvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"exemestane","indication_name":"Advanced Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromasin","generic_name":"exemestane","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase Inhibitor [EPC]","quality_score":81,"revenue":"450","mechanism":"Aromasin works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens."},{"drug_id":"tisotumab","indication_name":"recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"TISOTUMAB","company_name":"Seagen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"147","mechanism":"Tivdak works by binding to a specific target on cancer cells, triggering an immune response to destroy the cancer."},{"drug_id":"tisotumab-vedotin","indication_name":"Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"tisotumab-vedotin","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"147","mechanism":"Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells."},{"drug_id":"tivdak","indication_name":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tisotumab Vedotin","generic_name":"tivdak","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":10,"revenue":"147","mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab and in patients who are not eligible for pembrolizumab plus durvalumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab and in patients who are not eligible for pembrolizumab plus durvalumab and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan plus cetrelimab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Triple-negative breast cancer with disease progression on or after chemotherapy in the neoadjuvant or adjuvant setting and/or in patients with measurable disease by RECIST v1.1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fluvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"penpulimab","indication_name":"Metastatic Non-Keratinizing Nasopharyngeal Carcinoma with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penpulimab kcqx","generic_name":"PENPULIMAB","company_name":"Akeso Biopharma","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer."},{"drug_id":"aromasin","indication_name":"Advanced Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aromasin","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Androgen receptor, Aromatase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"myoinositol","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"fulvestrant","indication_name":"Metastatic Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Faslodex","generic_name":"fulvestrant","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":58,"revenue":null,"mechanism":"Faslodex works by binding to and degrading the estrogen receptor, preventing it from promoting the growth of cancer cells."},{"drug_id":"lipitor","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in postmenopausal women with disease progression following prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tarlatamab","indication_name":"ES-SCLC with disease progression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"lovastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"faslodex","indication_name":"Metastatic Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Faslodex","company_name":"Translational Oncology Research International","drug_phase":"marketed","molecular_target":"NAD-dependent protein deacylase sirtuin-5, mitochondrial, Bifunctional epoxide hydrolase 2, G-protein coupled estrogen receptor 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"inositol","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":62,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04505722","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":44325,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04614948","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31835,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05791630","title":"The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)","phase":"NA","overall_status":"RECRUITING","enrollment_count":23650,"lead_sponsor_name":"Ostfold Hospital Trust","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT05580666","title":"Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT04213664","title":"Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.","phase":"","overall_status":"UNKNOWN","enrollment_count":4666,"lead_sponsor_name":"Corporacion Parc Tauli","has_results":false},{"nct_id":"NCT07494799","title":"Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3890,"lead_sponsor_name":"Tianjin Medical University Eye Hospital","has_results":false},{"nct_id":"NCT06480617","title":"Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT03892577","title":"Real-world Study for Patients With Advanced Hepatobiliary Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03451929","title":"Kidney Function and Cardiovascular Events: Cohort Study in General Population","phase":"","overall_status":"UNKNOWN","enrollment_count":2746,"lead_sponsor_name":"María Pilar Gayoso Diz","has_results":false},{"nct_id":"NCT06623760","title":"Study on the Impact of Desk and Chair Adaptation Intervention on the Occurrence and Development of Myopia in Primary School Students","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Fangbiao Tao","has_results":false},{"nct_id":"NCT05796700","title":"Microwave Ablation Versus Laparoscopic Hepatectomy for 3-5cm Hepatocellular Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":1585,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04581122","title":"A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06498947","title":"Factors Influencing Physiological Hyperopia in Children","phase":"","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT03509779","title":"Pronostic and Predictive Value of EMT in Localized Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"European Georges Pompidou Hospital","has_results":false},{"nct_id":"NCT04370860","title":"Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05679986","title":"Early Neurological Deterioration in Recent Small Subcortical Infarction","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Yuan Gao","has_results":false},{"nct_id":"NCT06306170","title":"Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04050215","title":"68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":937,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03349385","title":"Registry of Secondary Revascularization","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":869,"lead_sponsor_name":"Hospital San Carlos, Madrid","has_results":false},{"nct_id":"NCT07008716","title":"Omitting CTV for Primary Tumor in LS-SCLC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":852,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07516223","title":"MRI-Assisted Guidance for Non-Essential Tissue Sampling","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Shanghai East Hospital","has_results":false},{"nct_id":"NCT03121768","title":"A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"","overall_status":"UNKNOWN","enrollment_count":761,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT03332368","title":"Clinical Study on Triple Negative Breast Cancer With Chinese Medicine","phase":"","overall_status":"UNKNOWN","enrollment_count":620,"lead_sponsor_name":"Sheng Liu","has_results":false},{"nct_id":"NCT06708156","title":"The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Oupushifang Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT05784428","title":"Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression","phase":"NA","overall_status":"RECRUITING","enrollment_count":598,"lead_sponsor_name":"Robert Olson","has_results":false},{"nct_id":"NCT04422223","title":"Prospective Cohort Study of Disease and Outcomes in Cirrhosis","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Copenhagen University Hospital, Hvidovre","has_results":false},{"nct_id":"NCT04491994","title":"Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"UNICEF","has_results":true},{"nct_id":"NCT01980212","title":"Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT05184829","title":"A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04772768","title":"Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT05688709","title":"Acceptability, Feasibility and Effectiveness of Online Peer Support Group for ART Adherence Among Youth","phase":"NA","overall_status":"UNKNOWN","enrollment_count":488,"lead_sponsor_name":"Infectious Diseases Research Collaboration, Uganda","has_results":false},{"nct_id":"NCT05477797","title":"Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT07424560","title":"Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Zhilong Dong","has_results":false},{"nct_id":"NCT05310370","title":"HRD and Resistance to PAPPi in EOC Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03174912","title":"In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Ankara Training and Research Hospital","has_results":false},{"nct_id":"NCT06631339","title":"Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)","phase":"NA","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"National University of Singapore","has_results":false},{"nct_id":"NCT03617757","title":"Progression From Impaired Fasting Glucose to Diabetes Mellitus Among Chinese","phase":"NA","overall_status":"COMPLETED","enrollment_count":386,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06276088","title":"Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":374,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05407740","title":"\"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease\"Disease","phase":"","overall_status":"COMPLETED","enrollment_count":355,"lead_sponsor_name":"Soutien aux Actions contre les Maladies du Globule Rouge","has_results":false},{"nct_id":"NCT07382570","title":"Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":330,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT05800093","title":"Proteomics and Genomics Combined With CT to Predict CVD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":310,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT07342478","title":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":306,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT05310357","title":"Chromosomal Instability in Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05663242","title":"The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","has_results":false},{"nct_id":"NCT06527001","title":"Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT05085275","title":"Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"USRC Kidney Research","has_results":true},{"nct_id":"NCT05679518","title":"Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches","phase":"NA","overall_status":"RECRUITING","enrollment_count":261,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07514039","title":"Photolithography Microstructure Myopia Management Lenses in Preventing and Controlling Myopia in Children and Adolescents","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":252,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT06577376","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":252,"lead_sponsor_name":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}